Recombinant Zebrafish ADM2A

• Cat.No.: ADM2A-7066Z
• Product Overview: Recombinant Zebrafish ADM2A full length or partial length protein was expressed.

Specification

• Source: Mammalian Cells
• Species: Zebrafish
• Tag: His
• Form: Liquid or lyophilized powder
• Endotoxin: < 1.0 eu per μg of the protein as determined by the LAL method.
• Purity: >80%
• Notes: This item requires custom production and lead time is between 5-9 weeks. We can custom produce according to your specifications.
• Storage: Store it at +4 oC for short term. For long term storage, store it at -20 oC～-80 oC.
• Storage Buffer: PBS buffer

Gene Information

• Gene Name: adm2a adrenomedullin 2a [ Danio rerio (zebrafish) ]
• Official Symbol: ADM2A
• Gene ID: 403114
• mRNA Refseq: NM_001130135
• Protein Refseq: NP_001123607
• UniProt ID: B3DJI5

Reviews

06/19/2020

Another feature that sets the ADM2A protein apart from other similar products is its long-term stability.

10/29/2019

This versatility allows me to conduct multiple types of experiments efficiently with a single product, ultimately saving me time and resources.

08/31/2019

the responsiveness of their technical support team has been exceptional, promptly addressing any questions or concerns I have had.

03/01/2018

I am very impressed by the quality of the ADM2A protein and the level of support provided by its manufacturer, making it an ideal choice for my research needs.

Q&As

Could ADM2A agonists have applications beyond pain and psychiatric disorders?

There is potential for ADM2A agonists to have applications beyond pain and psychiatric disorders. Research has shown that ADM2A signaling plays a role in inflammation and immune response, and ADM2A agonists may have potential as treatments for inflammatory conditions such as rheumatoid arthritis and inflammatory bowel disease. Additionally, ADM2A agonists have been shown to stimulate insulin secretion and improve glucose metabolism in animal models, raising the possibility of their use in the treatment of diabetes.

How have ADM2A proteins been targeted in drug development?

ADM2A proteins have been targeted in drug development by the use of ADM2A agonists, which activate the receptor and produce pain-relieving effects. Several of these drugs are currently in development, including Adlea (Lidocaine HCl 10% Injection) and ZP131, a novel ADM2A agonist.

What are the potential benefits of ADM2A agonists in pain management?

ADM2A agonists provide a potential alternative to opioids for pain management, as they do not produce the same addictive effects or risk of overdose. They also have the potential to provide pain relief without causing respiratory depression or other adverse effects. Additionally, ADM2A agonists may offer a new approach to pain management for individuals who are unable to take or do not want to take opioids.

Are there any ADM2A agonists currently approved for medical use?

No ADM2A agonists have been approved for medical use at this time. However, there are several compounds in development that target this receptor and show promise as potential therapeutics. One example is a compound called ADMP, which is being developed by Adynxx, Inc. for the treatment of pain. ADMP has shown positive results in early-stage clinical trials, and the company is currently conducting further testing to evaluate its safety and efficacy. Other companies and academic institutions are also exploring the potential of ADM2A agonists in various therapeutic applications.

Are there any side effects associated with ADM2A agonists?

As ADM2A agonists are still being researched, their side effects are not yet fully understood. However, some early studies suggest that ADM2A agonists may cause gastrointestinal side effects, including nausea and vomiting. Additionally, ADM2A agonists may interact with other medications, so caution should be exercised when combining them with other drugs.

Could ADM2A agonists eventually replace opioids as a treatment for pain?

ADM2A agonists have the potential to provide a safer alternative to opioids for pain management. However, further research is needed to fully understand the risks and benefits of ADM2A agonists in comparison to opioids. ADM2A agonists may also be used in combination with other pain medications or non-pharmacological therapies to provide more effective pain management strategies.

How are ADM2A proteins implicated in psychiatric disorders?

ADM2A proteins are widely expressed in the brain, particularly in regions involved in mood regulation, such as the prefrontal cortex and amygdala. Studies have indicated that ADM2A signaling may be disrupted in individuals with depression, anxiety disorders, and schizophrenia. This suggests that ADM2A agonists may have potential as treatments for these conditions.

How do ADM2A agonists compare to other pain medications, such as opioids and nonsteroidal anti-inflammatory drugs (NSAIDs)?

ADM2A agonists may offer a safer alternative to opioids for pain management, as they do not produce the same level of respiratory depression or dependence. Additionally, ADM2A agonists may have a lower risk of gastrointestinal bleeding and other side effects associated with NSAIDs. However, it is important to note that ADM2A agonists are still being researched and their long-term safety and efficacy are not yet fully understood.

Can ADM2A agonists be used in combination with other pain medications?

ADM2A agonists may be used in combination with other pain medications or non-pharmacological therapies to provide more effective pain management strategies. However, caution should be exercised when combining ADM2A agonists with other drugs, as there may be interactions that could affect their efficacy or safety. It is important to consult with a healthcare provider before combining any medications or therapies.

Are there any potential risks associated with the use of ADM2A agonists?

Like all medications, ADM2A agonists may have potential risks and side effects. However, early clinical trials have suggested that ADM2A agonists are generally well-tolerated and do not produce the same adverse effects as opioids. Further research is needed to fully understand the risks and potential benefits of ADM2A agonists.

What other potential medical applications could ADM2A agonists have?

In addition to pain management, ADM2A agonists have the potential to be used in the treatment of other medical conditions. Research has shown that ADM2A proteins are involved in the regulation of mood, anxiety, and stress, suggesting that ADM2A agonists may have potential as treatments for depression and anxiety disorders. ADM2A agonists may also have anti-inflammatory effects, which could make them useful for the treatment of conditions such as arthritis and inflammatory bowel disease.